[ET Net News Agency, 15 October 2019] China Grand Pharmaceutical and Healthcare
Holdings Limited (00512) said an innovative coronary intervention product "Paclitaxel
Releasing Coronary Balloon Dilatation Catheter", being co-developed by the group and
Cardionovum GmbH, has been recently granted the medical device registration certificate by
National Medical Products Administration of PRC. The group will be responsible for the
promotion and distribution of such products in the PRC.
As one of the percutaneous coronary interventions (PCI) treatment products being
expected by the expert in the cardiovascular field, the product currently is the first and
the only product in the PRC market which is able to treat 2 indications, namely in-stent
restenosis and small vessel disease. It reflects a wide range of clinical value and market
prospects. (RC)